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Acute infection, if not rapidly and accurately detected, can lead to sepsis, organ failure
and even death. Current detection of acute infection as well as assessment of a patient’s
severity of illness are imperfect. Characterization of a patient’s immune response by quanti-
fying expression levels of specific genes from blood represents a potentially more timely and
precise means of accomplishing both tasks. Machine learning methods provide a platform
to leverage this host response for development of deployment-ready classification models.
Prioritization of promising classifiers is dependent, in part, on hyperparameter optimiza-
tion (HO) for which a number of approaches including grid search, random sampling and
Bayesian optimization have been shown to be effective. We compare HO approaches for
the development of diagnostic classifiers of acute infection and in-hospital mortality from
gene expression of 29 diagnostic markers. We take a deployment-centered approach to our
comprehensive analysis, accounting for heterogeneity in our multi-study patient cohort with
our choices of dataset partitioning and hyperparameter optimization objective as well as as-
sessing selected classifiers in external (as well as internal) validation. We find that classifiers
selected by Bayesian optimization for in-hospital mortality can outperform those selected by
grid search or random sampling. However, in contrast to previous research: 1) Bayesian opti-
mization is not more efficient in selecting classifiers in all instances compared to grid search
or random sampling-based methods and 2) we note marginal gains in classifier performance
in only specific circumstances when using a common variant of Bayesian optimization (i.e.
automatic relevance determination). Our analysis highlights the need for further practical,
deployment-centered benchmarking of HO approaches in the healthcare context.
Keywords: hyperparameter optimization; Bayesian optimization; acute infection; sepsis; dis-
ease severity; mortality; classification; molecular diagnostics; genomics.
1. Introduction
Patient lives depend on the swiftness and accuracy of 1) assessment of the severity of their
illness and 2) detection of acute infection (when present). The COVID-19 pandemic has put
this fact into stark relief. Currently, clinicians determine severity of illness by computing scores
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(e.g. SOFA1) based on patient physiological features associated with the risk of adverse events
(e.g. in-hospital mortality, organ failure). Similarly, detection of acute infection generally in-
volves evaluation of symptoms (e.g. cough, runny nose, fever) as well as laboratory tests for
the presence of specific pathogens. However, these methods provide superficial and imprecise
measures of patient illness. Recent work has highlighted the potential of using gene expression
measurements from patient blood to detect the presence and type of infection to which the
patient is responding2–5 as well as the patient’s severity of illness.6
Coupled with these host response signatures, advances in machine learning (ML) provide
a platform for the development of robust, diagnostic classifiers of acute infection status (e.g.
bacterial or viral) and in-hospital mortality from gene expression. An important step in this
development is optimization of the classifier’s hyperparameters: aspects of the model that
affect its complexity (e.g. penalty coefficient in a LASSO logistic regression) as well as how
it’s trained (e.g. learning rates for stochastic gradient descent). Hyperparameter optimization
begins with specification of a search space and proceeds by generating a user-specified number
of hyperparameter configurations (HCs; sets of specific hyperparameter values corresponding
to a unique classification model), training the classifier models given by each configuration, and
evaluating the performance of the trained classifier in internal validation. Internal validation
performance is typically assessed either on a separate validation/tuning dataset or by cross-
validation. Hyperparameter configurations are then ranked by this performance, with the top
configuration selected and retained for external validation (application to a held-out dataset).
Multiple HO approaches have been proposed. For classifiers with relatively small hyper-
parameter spaces (e.g. support vector machines), optimizing over a pre-defined grid of hy-
perparameter values (grid search; GS) has proven effective. More recent work has shown
that optimization by randomly sampling (RS) hyperparameter configurations can lead to
better coverage of high-dimensional hyperparameter spaces and potentially better classifier
performance.7 Bayesian optimization (BO) is a global optimization procedure that has found
success in applications as wide-ranging as viral capsid assembly,8 genetic pre-breeding,9 high-
throughput RNA sequencing assembly10 and materials design.11 BO has also proven effective
for hyperparameter optimization in classical12–16 and biomedical17–20 ML applications. In BO,
one uses a model (commonly a Gaussian process (GP)21) to approximate the objective func-
tion one wants to optimize; for hyperparameter optimization, the objective function maps from
hyperparameter configurations to the internal validation performance of their corresponding
classifiers. In contrast to GS/RS, BO proceeds by sequentially evaluating configurations with
each newly visited configuration used to update the model of the objective function.
In this work, we compare GS/RS and BO methods for hyperparameter optimization of
gene expression-based diagnostic classifiers for two clinical tasks: 1) detection of acute infec-
tion and 2) prediction of mortality within 30 days of hospitalization. We optimize and train
three different types of classifiers using gene expression features from 29 diagnostic markers
in a multi-study cohort of 3413 patient samples for acute infection detection (3288 for 30-
day mortality prediction). Patient samples were assayed on a variety of technical platforms
and collected from a range of geographical regions, healthcare settings, and disease contexts.
Our extensive analysis evaluates the BO approach, in particular, under a range of compu-
tational budgets and optimization settings. Crucially, beyond assessing and comparing the
performance of top classifiers in internal validation, we further evaluate top models selected
by all HO approaches in a multi-cohort external validation set comprising nearly 300 patients
profiled by a targeted diagnostic instrument (NanoString). Our analysis provides important
insights for diagnostic classifier development using genomic data, and, more generally, about
the implementation and practical usage of HO methods in healthcare.
2. Related Work
Previous studies comparing HO approaches in the ML community have demonstrated that
BO can select promising classifiers more efficiently (with fewer evaluations of hyperparame-
ter configurations) than GS/RS methods.12–16,19,20,22 However, these studies have focused on
internal validation performance and on benchmark datasets whose composition and handling
(i.e. partitioning into training-validation-test splits) doesn’t necessarily reflect characteristics
of healthcare settings (i.e. smaller, structured, and more heterogeneous datasets; high propen-
sity for models to be applied to out-of-distribution samples at test time).
Bayesian optimization has also found recent success in genomics and biomedical applica-
tions. Ghassemi et al.17 compare multiple HO approaches, including BO, for tuning parameters
of the multi-scale entropy of heart rate time series to aid mortality prediction among sepsis
patients. Colopy et al.18 analyzed RS and BO methods for optimization of patient-specific
GP regression models used in vital-sign forecasting. A study by Nishio et al.19 evaluated both
RBF SVM and XGBoost classifiers tuned by either RS or BO for detection of lung can-
cer from nodule CT scans. Borgli et al.20 evaluated BO for tuning and transfer learning of
pre-trained convolutional neural networks to detect gastrointestinal conditions from images.
Again, however, these studies either reported internal validation performance or performance
on a test set partitioned from a full (often small; on the order of 100s of samples) dataset
that was collected from a single hospital, making conclusions difficult to draw about the gen-
eralizability of selected models in other segments of the deployment population. Moreover,
these studies focused on: 1) no more than two classifier types, 2) a narrow range of settings
for BO, and 3) physiological or image data. To our knowledge, no studies have evaluated the
external validation performance of selected models, an important pre-requisite for eventual
model deployment. In addition, no comparison of HO approaches has yet been attempted for
development of diagnostic classifiers using genomic data.
3. Methods
3.1. Cohort & Feature Description
To build our datasets, we combined gene expression data from public sources and in-house
clinical studies designed for research in diagnosing acute infections and sepsis. We collected the
publicly available studies from the NCBI GEO and EMBL-EBI ArrayExpress databases using
a systematic search.2 The public studies were profiled using a variety of different technical
platforms (e.g. mostly from microarrays). Samples from the in-house clinical studies were
profiled on the NanoString nCounter platform using a custom codeset for 29 diagnostic genes
of interest. All included studies consisted of samples from our target population, comprising
both adult and pediatric patients from diverse geographical regions and clinical settings. Each
included study had measurements taken from patient blood for all 29 markers.
The features we used in our analyses were based on the expression values of 29 genes
previously found to accurately discriminate three different aspects of acute infection: 1) viral
vs. bacterial infection (7 genes),3 2) infection vs. non-infectious inflammation (11 genes),2
and 3) high vs. low risk of 30-day mortality (11 genes).6 Building on our previous work,5
we computed both the geometric means and arithmetic means of these six groups of genes,
producing 12 features. We optimized and trained our classifiers on the combination of these 12
features and the expression values of all 29 genes (41 features in total). Labels for one of three
classes of the acute infection detection or BVN task (Bacterial infection, Viral infection, or
Non-infectious inflammation) were determined by multiple-physician adjudication after chart
review and not necessarily by positive pathogen identification. Non-infected determinations
did not include healthy controls. Binary indicator labels of whether a patient died within 30
days of hospitalization were used for the mortality task. We derived these labels from study
metadata (when available) and the associated study’s manuscripts.
For both tasks, we separated studies into a training set and an external validation set.
For the BVN task, the training set consisted of 43 studies (profiled outside Inflammatix) and
3413 patients (1087 with bacterial infection, 1244 with viral infection, and 1082 non-infected).
The BVN external validation set consisted of six studies (profiled by Inflammatix) and 293
patients (153 with bacterial infection, 106 with viral infection, and 34 non-infected). For the
mortality task, the training set consisted of 33 studies (profiled outside Inflammatix) and 3288
patients (175 30-day mortality events) while the mortality external validation set comprised
four studies (profiled by Inflammatix) and 348 patients (80 30-day mortality events).
3.2. Grouped cross-validation
Previous analyses by our group5 suggested that alternative cross-validation strategies were
preferable over conventional k-fold CV for identifying classifiers able to generalize across het-
erogeneous patient populations. We use 5-fold grouped CV (full studies are allocated to one
and only one of five folds) to rank and select hyperparameter configurations from GS/RS
methods and as an objective function in BO.
3.3. Classifier types and performance assessment
We evaluated three types of classification models: 1) support vector machines with a radial
basis function (RBF) kernel, 2) XGBoost (XGB23) and 3) multi-layer perceptrons (MLP).
MLP models were trained with the Adam optimizer24 with mini-batch size fixed at 128.
For the BVN task, we ranked and selected models based on multi-class AUC (mAUC).25
For the mortality task, we used binary AUC as our performance metric. We opted for AUC
(as opposed to other metrics suited to class imbalance in the mortality task) due to its clinical
acceptance. To determine performance of models in grouped 5-fold CV, we pooled the model’s
predicted probabilities for each fold and computed the relevant metric (mAUC or AUC) from
the pooled probabilities. The top hyperparameter configuration for each task and optimiza-
tion run was then trained on the full training set and applied to the external validation set.
We computed external validation performance (either mAUC or AUC) for these top models
using their predicted probabilities for the validation samples. We computed 95% bootstrap
confidence intervals for differences in classification performance by sampling predicted prob-
abilities with replacement 5000 times (using the same set of bootstrap sample IDs for both
sets of predicted probabilities in the comparison), computing the relevant performance metric
on each bootstrap sample, computing the difference between performance metrics for each
bootstrap sample in a given comparison, and reporting the 2.5th and 97.5th quantiles of the
5000 bootstrap samples of the differences.
3.4. Hyperparameter optimization details
For RBF SVM, we conduct a grid search over configurations of the cost, C, and bandwidth
hyperparameters, γ. C values ranged from 1e-03 to 2.15 and γ values ranged from 1.12e-04
to 10. We generated RS samples for XGBoost and MLP uniformly and independently of one
another from pre-specified ranges or from grids (Suppl. Tables 1 and 2).
In our analyses with BO, the objective function maps from hyperparameter configurations
to 5-fold grouped CV performance of the corresponding classifiers. The two main components
of BO are: 1) a model that approximates the objective function, and 2) an acquisition function
to propose the next configuration to visit in hyperparameter space. We use a GP regression
model with Gaussian noise to approximate the objective function. Each BO run consists of
two stages: 1) initialization and 2) optimization. In the initialization stage, we uniformly and
independently sample configurations (either 5 or 25) from the hyperparameter space to seed
construction of the GP approximation of the objective function.
We investigate both the expected improvement (EI) and upper confidence bound (UCB)
acquisition functions. We use both standard and automatic relevance determination (ARD)
forms of the Matern5/2 covariance function in BO’s GP model of the objective (further details
in Supplement). We also perform BO in the hyperparameters’ native scales (original space) or
in which continuous and discrete hyperparameter dimensions are searched in the continuous
range 0 to 1 and transformed back to their native scales prior to their evaluation (transformed).
4. Results
We compared BO and GS/RS approaches for hyperparameter optimization of three types of
classifiers for two clinical tasks. For the BVN task, we sought classifiers that could achieve
high performance in predicting whether a patient had a bacterial or viral infection or was
showing a non-infectious inflammatory response. For the mortality task, we sought classifiers
that could achieve high performance in predicting mortality events within 30 days of hospital
admission. Though we considered BO at two initialization budgets (5 and 25 configurations),
we did not see substantial differences in performance between classifiers with 5 and 25 initial
configurations (Suppl. Table 3, Suppl. Figs. 1 and 2). We focus on BO results with 25 initial
configurations and the EI acquisition function for the remainder of this work.
General comparison of classifier performance across tasks and HO approaches
Across both tasks and HO approaches, we note distinct performance characteristics of the
selected classifiers of each type. While RBF SVM classifiers performed similarly to the other
two classifier types on the BVN task, they were the worst performers on the mortality task.
XGB classifiers selected by either RS or BO demonstrated competitive performance in both
tasks and were remarkably consistent in their performance regardless of the number of hyper-
parameter configurations evaluated for HO. MLPs achieved the highest internal and external
validation performance for both acute infection detection and mortality prediction (Table 1),
suggesting potential benefits of learning latent features (hidden layers) for these tasks.
Model
HO
Type
No. of
Evals. ARD
BVN
CV
BVN
Val.
Mort.
CV
Mort.
Val.
RBF
GS 10 - 0.808 0.862 0.758 0.736
GS 50 - 0.814 0.853 0.797 0.739
GS 100 - 0.814 0.853 0.800 0.782
GS 250 - 0.814 0.853 0.801 0.749
GS 500 - 0.815 0.853 0.801 0.749
GS 1000 - 0.815 0.853 0.839 0.708
GS 5000* - 0.815 0.853 0.839 0.708
BO 10 Y 0.811 0.788 0.800 0.747
BO 10 N 0.815 0.851 0.800 0.746
BO 50 Y 0.816 0.852 0.801 0.752
BO 50 N 0.816 0.852 0.801 0.749
BO 100 Y 0.816 0.852 0.800 0.753
BO 100 N 0.816 0.852 0.801 0.752
XGB
RS 50 - 0.809 0.830 0.880 0.819
RS 100 - 0.813 0.827 0.885 0.819
RS 250 - 0.812 0.826 0.885 0.829
RS 500 - 0.810 0.829 0.885 0.826
RS 1000 - 0.810 0.822 0.885 0.822
RS 5000 - 0.813 0.830 0.888 0.823
RS 25000 - 0.815 0.860 0.889 0.816
BO 50 Y 0.818 0.865 0.887 0.814
BO 50 N 0.812 0.828 0.881 0.817
BO 100 Y 0.811 0.825 0.885 0.825
BO 100 N 0.809 0.826 0.878 0.817
BO 250 Y 0.818 0.865 0.886 0.826
BO 250 N 0.816 0.834 0.882 0.802
BO 500 Y 0.818 0.865 0.889 0.827
BO 500 N 0.812 0.831 0.880 0.815
MLP
RS 50 - 0.818 0.860 0.763 0.631
RS 100 - 0.814 0.863 0.785 0.640
RS 250 - 0.824 0.861 0.807 0.625
RS 500 - 0.819 0.859 0.853 0.691
RS 1000 - 0.835 0.872 0.809 0.637
RS 5000 - 0.837 0.835 0.826 0.796
RS 25000 - 0.840 0.856 0.859 0.743
BO 50 Y 0.816 0.820 0.888 0.823
BO 50 N 0.814 0.824 0.888 0.820
BO 100 Y 0.822 0.845 0.886 0.847
BO 100 N 0.828 0.854 0.884 0.825
BO 250 Y 0.817 0.848 0.890 0.842
BO 250 N 0.832 0.832 0.889 0.812
BO 500 Y 0.837 0.855 0.894 0.835
BO 500 N 0.826 0.822 0.890 0.806
A. B.
Fig. 1. Differences in classification performance (points) on the BVN (A; mAUC) and mortality
(B; AUC) tasks for BO evaluation budgets. Differences greater than 0 indicate better performance
for the BO-selected classifier. Classifiers were selected using either BO or GS/RS with the indicated
number of HCs evaluated. Error bars represent 95% bootstrap confidence intervals of the difference
in performance.
Evaluation of BO- and GS/RS-selected classifiers at evaluation budgets typical
of BO. Previous studies have shown that BO can select promising classifiers more efficiently
(with fewer evaluations of hyperparameter configurations) than GS/RS methods. Surprisingly,
we find that at smaller numbers of configurations evaluated (more typical of BO), classifiers
selected by GS/RS showed similar or better performance in both internal and external vali-
dation (Table 1 and Figs. 1) when compared with corresponding BO-selected classifiers. We
observed similar trends when using the UCB acquisition function (Suppl. Fig. 3 and Suppl.
Table 4) or the transformed hyperparameter space (Suppl. Fig. 5 and Suppl. Table 5). How-
ever, we do note two specific instances in which BO-selected classifiers exceeded performance
of GS/RS-selected classifiers at smaller numbers of evaluated configurations: 1) XGBoost clas-
sifiers in external validation for the BVN task and 2) MLP classifiers for the mortality task.
While these two instances are consistent with prior findings of BO’s relative efficiency in se-
lecting classifiers, our results also suggest that simply committing to one HO approach over
another could miss models that generalize well and that performance of top selected classifiers
depends on the task and classifier type as well as the approach to HO.
Evaluation of BO- and GS/RS-selected classifiers at evaluation budgets typical of
GS/RS. In the previous analysis, we compared BO- and GS/RS-selected classifiers at eval-
uation budgets typical of BO (i.e. fewer configurations evaluated). In Figure 2, we compare
BO-selected classifiers from their highest evaluation budgets (100 evaluations for RBF and 500
evaluations for XGB and MLP) to classifiers selected by GS/RS at larger evaluation budgets.
Interestingly, we find that the BO-selected MLP classifiers for the mortality task continue
to outperform their corresponding RS-selected counterparts, even with 25000 configurations
evaluated for RS. Similarly, we find that BO-selected XGBoost classifiers exceed external val-
idation performance of RS-selected classifiers on the BVN task up to an RS evaluation budget
of 25000 configurations (though the differences do not persist at 25000 configurations). We
observe these performance differences when conducting BO with the UCB (vs. EI) acquisition
function or with a transformed hyperparameter space (Suppl. Figs. 4 and 6). These results
indicate the relative efficiency of BO in candidate classifier selection in these two instances
but also illustrate the competitiveness of GS/RS-selected classifiers in our setting.
A. B.
Fig. 2. Differences in classification performance on the BVN (A; mAUC) and mortality (B; AUC)
tasks for GS/RS evaluation budgets. Here, indicated evaluation budgets apply to GS/RS-selected
classifiers, whereas BO-selected classifiers are taken from 100-evaluation (RBF) or 500-evaluation
(XGB and MLP) runs.
Assessment of effects on classifier performance of automatic relevance determi-
nation in BO. For high-dimensional hyperparameter spaces, some hyperparameters may
have a greater impact on the model’s generalization performance than others. Automatic
relevance determination (ARD26) in the GP model of BO’s objective provides the means
to estimate effects of variations in hyperparameter dimensions on the objective’s value and
has been used in multiple implementations of BO (e.g. Snoek et al., 201212 and BoTorch,
https://botorch.org/docs/models). We directly compare the internal and external vali-
dation performance of classifiers selected by BO with and without ARD. In Figure 3, we
find that enabling ARD seems to lead to comparable if not slightly better internal validation
performance at higher evaluation budgets. Moreover, enabling ARD seems to improve exter-
nal validation performance for both XGB (BVN task) and MLP classifiers (both tasks). In
fact, the highest external validation performance by XGB classifiers on the BVN task is only
achieved with ARD enabled (Table 1). However, these differences in classifier performance are
not as evident when using the UCB acquisition function (Suppl. Fig. 7) or conducting BO
with a transformed version of the hyperparameter space (Suppl. Fig. 8). Thus, ARD may not
be necessary to select top-performing diagnostic classifiers for these two clinical tasks.
A. B.
Fig. 3. Differences in classification performance on the BVN (A; mAUC) and mortality (B; AUC)
tasks for BO-selected classifiers with or without ARD enabled (EI acquisition function, 25 initial-
ization configurations). Differences greater than 0 indicate better performance for the ARD-enabled
classifier. Error bars represent 95% bootstrap confidence intervals of the difference in performance.
5. Discussion & Conclusions
In this analysis, we carried out a comprehensive comparison of HO approaches for diagnostic
classifier development to determine what approach (if any) led to improvements in: 1) external
validation performance or 2) computational efficiency. Consistent with previous findings, we
found that BO was able to prioritize candidate classifiers for two tasks relevant to emergency
and critical care with a fraction of the configurations evaluated using GS/RS. As embar-
rassingly parallel approaches like GS/RS can necessitate the use of commodity computing
clusters, BO’s efficiency makes the approach a potentially cost-effective alternative to HO.
We also found that the external validation performance of MLP classifiers selected by BO for
prediction of in-hospital mortality was consistently better across a range of HO evaluation
budgets than the performance of classifiers selected by GS/RS, highlighting BO’s potential to
uncover diagnostic classifiers that generalize better to unseen patients.
However, and in contrast to previous comparisons of HO approaches, our analyses indicated
that GS/RS methods could select classifiers for both tasks with evaluation budgets comparable
to those used for BO. We also found mixed evidence in support of enabling ARD in the kernel
of BO’s GP model of the objective function. Thus, while we hoped we would uncover distinct
and general differences between HO approaches in order to develop better guidelines about
when (or even if) to use one approach over another, we did not identify such clear differences
across tasks, classifier types, and optimization settings. Rather, our analysis suggests that
both GS/RS and BO approaches should be investigated for classifier development.
We acknowledge limitations of our approach. For our RS runs, we sampled configurations
uniformly and independently from pre-defined ranges or grids of values. Other random sam-
pling approaches could’ve been used in which configurations are generated dependent on the
values of previously generated configurations (e.g. Latin hypercube or low-discrepancy Sobol
sequences) in order to encourage diversity of the resulting sample.7 A second limitation is that
we used a single set of features derived from a previously identified set of 29 gene expression
markers. We chose these features based on previous analyses5 and consistent with our goal
of developing diagnostic classifiers from these specific markers for clinical deployment. We
acknowledge our conclusions may not hold with other feature sets.
Throughout this work, we were mindful of the larger implications of HO on downstream
clinical deployment. Our choice of objective function (grouped 5-fold CV performance) and
our evaluation of performance in external validation were based on our experiences with
the smaller, more heterogeneous data regimes typical of biomedical research as well as our
expectation that we had likely not fully characterized the deployment population (patients to
which we would apply our selected classifiers). In our survey of other comparative studies of
HO, we noted important connections between assumptions about the deployment scenario and
about how well the deployment population was characterized by the training data with study
design choices about dataset partitioning and the objective function. For example, ML studies
primarily focused on larger (N >∼100k) datasets composed mainly of natural images. These
benchmarks were often constructed (e.g. MNIST; http://yann.lecun.com/exdb/mnist/) to
satisfy the assumption that the distribution of training and external validation samples are
similar if not the same. In this setting, one would expect that the correspondence between
a model’s internal and external validation performance should be strong: a model with the
best performance in optimization should have nearly the best, if not the best, performance
in a held-out dataset. Thus, optimizing a classifier in internal validation would be advisable,
especially when the training dataset fully captures the characteristics of the target population.
However, patient data is known to be heterogeneous due to biological differences as well
as differences in geography, healthcare delivery, and assay technologies used, suggesting that
the assumption of distributional similarity between training and external validation samples
is likely to be violated. A recent study by Google highlighted this challenge for deployment in
healthcare: their AI system for breast cancer screening showed drops in predictive performance
when trained on mammograms from the UK and applied to mammograms from the US.27 Our
recent work also found that estimates of generalization performance from internal validation
can be optimistically biased, even when accounting for technical/biological heterogeneity.5
Thus, regardless of the HO approach used, simply optimizing for internal validation perfor-
mance may still lead to overfitting of the resulting classifier. Thus, care should be taken before
rote application of HO techniques to ensure that the dataset partitioning, choice of objective
function, and, if possible, use of external validation data best account for characteristics of the
target population and the deployment scenario. For example, if deploying in a single hospital
or in a well-characterized or homogeneous population, performance of a candidate classifier in
conventional k-fold CV or on a held-out validation set may suffice for optimization and one
might expect good correspondence between internal and external validation performance. In
our setting, however, we assume that we have not fully characterized our target population,
owing to considerable patient heterogeneity and our desired deployment in multiple health-
care settings worldwide. Consequently, we opt for grouped k-fold CV as our internal validation
method and use our external validation performance to aid model selection.
In conclusion, we find that both GS/RS and BO remain promising avenues for hyper-
parameter optimization and represent key components in the development of more effective
diagnostics for emergency and critical care.
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Gene expression features & data processing
The features we used in our analyses were based on the expression values of 29 genes previously found to accurately discrim-
inate three different aspects of acute infection: 1) viral vs. bacterial infection (7 genes) [4], 2) infection vs. non-infectious
inflammation (11 genes) [3], and 3) high vs. low risk of 30-day mortality (11 genes) [2]. The 29 genes were grouped into six
modules based on positive or negative correlation with infection status or mortality risk: increased expression in viral infec-
tions (IFI27, JUP, LAX1), increased expression in bacterial infections (TNIP1, CTSB, HK3, GPAA1), increased (HIF1A,
SEPP1, RGS1, C11orf74, CD163, PER1, DEFA4, CIT) and decreased (LY86, TST, KCNJ2) expression in patients who
died within 28 days of hospitalization, increased (CEACAM1, ZDHHC19, C9orf95, GNA15, BATF, C3AR1) and decreased
(KIAA1370, TGFBI, MTCH1, RPGRIP1, HLA-DPB1) expression in patients with sepsis. Building on our previous work [1],
we computed both the geometric means and arithmetic means of these six groups of genes, producing 12 features. We
optimized and trained our classifiers on the combination of these 12 features and the expression values of all 29 genes (41
features in total).
We extracted gene expression measurements for all 29 diagnostic markers of interest and normalized these raw expression
values for each study. To account for technical and biological heterogeneity across the expression studies, we then performed
co-normalization (see [1]). We also collected labels for patient infection and mortality status. Labels for one of three classes of
the BVN task were determined by multiple-physician adjudication after chart review and not necessarily by positive pathogen
identification. Non-infected determinations did not include healthy controls. Binary indicator labels of whether a patient
died within 30 days of hospitalization were used for the mortality task. We derived these labels from study metadata (when
available) and the associated study’s manuscripts.
Bayesian optimization details
We evaluate Bayesian optimization with two different initialization budgets: 5 and 25 initial configurations. Our BO analyses
considered both the expected improvement (EI) and upper confidence bound (UCB) acquisition functions. We used the
Matern5/2 kernel in BO’s GP model of the objective function:
k(r) = σ2(1 +
√
5r +
5
3
r2)exp(−
√
5r) (1)
where
r =
√√√√ H∑
h=1
(xh − x′h)2
σ2l
. (2)
Here H is the dimensionality of the hyperparameter space, x and x′ are two configuration vectors being compared, σ2 is
the variance in the objective function’s value and σl is a lengthscale parameter that modulates the effect of changes in the
hyperparameter dimensions on changes in grouped 5-fold CV performance. In this formulation, there is a single lengthscale
parameter for all hyperparameter dimensions. We also assess the automatic relevance determination (ARD) form of the
Matern5/2 kernel in which each hyperparameter dimension has their own lengthscale parameter:
r =
√√√√ H∑
h=1
(xh − x′h)2
σ2l,h
(3)
.
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Implementation details
We used the RBF SVM implementation in Python3’s scikit-learn module (version 0.20.1). For XGBoost analyses, we used the
scikit-learn API in the xgboost package (version 0.90). All MLP models were implemented using Keras (version 2.1.6) with
a TensorFlow (version 1.8.0) back-end. We carried out all GS/RS analyses using our proprietary distributed HO software.
In our parallelized implementation of GS/RS, we first generate all configurations and then distribute the configurations to
multiple compute nodes in a commodity cluster for evaluation. We executed each GS/RS run using 100 t3a.large instances
(2 vCPUs/instance) from Amazon Web Services (AWS). We implemented BO analyses with the GPyOpt package [5] and
carried out BO on a personal laptop with an Intel Core i7-8550U at 1.80GHz 8-core CPU, running Ubuntu 18.04.
Hyperparameter space details
Table 1: XGBoost hyperparameter space. Shown are the values (for discrete and categorical hyperparameters) and
ranges (for continuous hyperparameters) over which optimization runs were conducted. We refer interested readers to
https://xgboost.readthedocs.io/en/latest/parameter.html for a more in-depth description of the different hyperpa-
rameters. Where relevant, we indicate when continuous hyperparameters were optimized in log scale and subsequently
transformed. All other model parameters were left at default values.
Hyperparameter Type Values
booster categorical [’gbtree’,’gblinear’,’dart’]
gamma continuous (0,5)
learning rate (eta) continuous (0.001,0.1)
L1 regularization term (alpha) continuous (0,1)
L2 regularization term (lambda) continuous (0,4.5)
maximum delta step discrete [0,1]
maximum tree depth discrete [3,4,5,6,7,8,9,10]
minimum child weight discrete [1,2,3,4,5]
number of boosting rounds continuous (log) (4.60517,6.907755)
subsample ratio of
columns for each level continuous (0.7,1)
subsample ratio of
columns for each node continuous (0.5,1)
subsample ratio of
columns for each tree continuous (0.7,1)
subsample ratio of
training instances continuous (0.3,1)
Table 2: MLP hyperparameter space. Shown are the values (for discrete and categorical hyperparameters) and ranges (for
continuous hyperparameters) over which optimization runs were conducted. Where relevant, we indicate when continuous
hyperparameters were optimized in log scale and subsequently transformed or optimized on a continuous range and converted
to the nearest integer (int).
Hyperparameter Type Values
training iterations discrete [50,100,250,500,1000,2500]
number of hidden layers discrete [1,2,3,4,5]
number of nodes
per hidden layer discrete
[2,3,4,5,6,7,8,9,10,11,12,13,
14,15,16,17,18,19,20,21]
activation type categorical
[’ELU’,’ReLU’,’sigmoid’,
’tanh’,’Leaky ReLU’]
perform dropout? categorical [True,False]
dropout rate
(input layer) continuous (0.0,0.5)
dropout rate
(fully-connected layers) continuous (0.0,0.5)
weight regularization type categorical [’None’,’L1’,’L2’]
L1 regularization term continuous (log) (-11.512925464970229,0.0)
L2 regularization term continuous (log) (-11.512925464970229, 0.0)
learning rate continuous (log)
(-11.512925464970229,
-2.3025850929940455)
weight initialization seed discrete [10,11,12,...,10000]
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A. B.
Figure 1: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for BO evaluation budgets with the EI acquisition function and 5 initialization configurations in the original
hyperparameter space. Differences greater than 0 indicate better performance for the BO-selected classifier. Classifiers were
selected using either BO or GS/RS with the indicated number of evaluations. Points represent observed differences while
error bars represent 95% bootstrap confidence intervals of the difference in performance.
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A. B.
Figure 2: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for GS/RS evaluation budgets with the EI acquisition function and 5 initialization configurations in the
original hyperparameter space. Similar layout to Figure 1 except that the indicated evaluation budgets only apply to
GS/RS-selected classifiers. BO-selected classifiers are taken from 100-evaluation (RBF) or 500-evaluation (XGB and MLP)
runs.
A. B.
Figure 3: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mor-
tality (B; AUC) tasks for BO evaluation budgets with the UCB acquisition function and 25 initialization configurations in
the original hyperparameter space. Differences greater than 0 indicate better performance for the BO-selected classifier.
Classifiers were selected using either BO or GS/RS with the indicated number of evaluations. Points represent observed
differences while error bars represent 95% bootstrap confidence intervals of the difference in performance.
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Table 3: Grouped 5-fold CV and external validation (Val.) performance of selected classifiers for the BVN and mortality
(Mort.) tasks. BO runs were performed in the original hyperparameter space with the EI acquisition function and 5
initialization configurations at the indicated evaluation budgets. Bold numbers indicate the best performance for a column.
Model
HO
Type
No. of
Evals. ARD
BVN
CV
BVN
Val.
Mort.
CV
Mort.
Val.
RBF
GS 10 - 0.808 0.862 0.758 0.736
GS 50 - 0.814 0.853 0.797 0.739
GS 100 - 0.814 0.853 0.800 0.782
GS 250 - 0.814 0.853 0.801 0.749
GS 500 - 0.815 0.853 0.801 0.749
GS 1000 - 0.815 0.853 0.839 0.708
GS 5000* - 0.815 0.853 0.839 0.708
BO 10 Y 0.809 0.859 0.800 0.746
BO 10 N 0.811 0.851 0.799 0.755
BO 50 Y 0.816 0.851 0.800 0.749
BO 50 N 0.815 0.852 0.800 0.745
BO 100 Y 0.816 0.852 0.800 0.750
BO 100 N 0.816 0.852 0.801 0.745
XGB
RS 50 - 0.809 0.830 0.880 0.819
RS 100 - 0.813 0.827 0.885 0.819
RS 250 - 0.812 0.826 0.885 0.829
RS 500 - 0.810 0.829 0.885 0.826
RS 1000 - 0.810 0.822 0.885 0.822
RS 5000 - 0.813 0.830 0.888 0.823
RS 25000 - 0.815 0.860 0.889 0.816
BO 50 Y 0.809 0.822 0.883 0.819
BO 50 N 0.809 0.816 0.877 0.801
BO 100 Y 0.818 0.864 0.883 0.827
BO 100 N 0.812 0.827 0.889 0.827
BO 250 Y 0.812 0.834 0.888 0.827
BO 250 N 0.810 0.827 0.881 0.814
BO 500 Y 0.811 0.829 0.887 0.821
BO 500 N 0.814 0.826 0.883 0.815
MLP
RS 50 - 0.818 0.860 0.762 0.631
RS 100 - 0.814 0.863 0.785 0.640
RS 250 - 0.824 0.861 0.807 0.625
RS 500 - 0.819 0.859 0.853 0.691
RS 1000 - 0.835 0.872 0.809 0.637
RS 5000 - 0.837 0.835 0.826 0.796
RS 25000 - 0.840 0.856 0.859 0.743
BO 50 Y 0.822 0.847 0.888 0.833
BO 50 N 0.817 0.864 0.883 0.819
BO 100 Y 0.829 0.853 0.889 0.809
BO 100 N 0.828 0.856 0.890 0.829
BO 250 Y 0.828 0.854 0.886 0.800
BO 250 N 0.833 0.850 0.888 0.820
BO 500 Y 0.831 0.865 0.893 0.837
BO 500 N 0.844 0.856 0.889 0.796
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Table 4: Grouped 5-fold CV and external validation (Val.) performance of selected classifiers for the BVN and mortality
(Mort.) tasks. BO runs were performed in the original hyperparameter space with the UCB acquisition function and 25
initialization configurations at the indicated evaluation budgets. Bold numbers indicate the best performance for a column.
Model
HO
Type
No. of
Evals. ARD
BVN
CV
BVN
Val.
Mort.
CV
Mort.
Val.
RBF
GS 10 - 0.808 0.862 0.758 0.736
GS 50 - 0.814 0.853 0.797 0.739
GS 100 - 0.814 0.853 0.800 0.782
GS 250 - 0.814 0.853 0.801 0.749
GS 500 - 0.815 0.853 0.801 0.749
GS 1000 - 0.815 0.853 0.839 0.708
GS 5000* - 0.815 0.853 0.839 0.708
BO 10 Y 0.814 0.851 0.800 0.746
BO 10 N 0.816 0.851 0.800 0.752
BO 50 Y 0.816 0.852 0.801 0.752
BO 50 N 0.816 0.852 0.806 0.726
BO 100 Y 0.816 0.852 0.801 0.748
BO 100 N 0.815 0.851 0.818 0.796
XGB
RS 50 - 0.809 0.830 0.880 0.819
RS 100 - 0.813 0.827 0.885 0.819
RS 250 - 0.812 0.826 0.885 0.829
RS 500 - 0.810 0.829 0.885 0.826
RS 1000 - 0.810 0.822 0.885 0.822
RS 5000 - 0.813 0.830 0.888 0.823
RS 25000 - 0.815 0.860 0.889 0.816
BO 50 Y 0.818 0.865 0.881 0.816
BO 50 N 0.810 0.825 0.881 0.819
BO 100 Y 0.811 0.825 0.888 0.821
BO 100 N 0.808 0.812 0.882 0.822
BO 250 Y 0.818 0.865 0.890 0.821
BO 250 N 0.811 0.823 0.882 0.821
BO 500 Y 0.818 0.865 0.888 0.821
BO 500 N 0.816 0.826 0.885 0.825
MLP
RS 50 - 0.818 0.860 0.762 0.631
RS 100 - 0.814 0.863 0.785 0.640
RS 250 - 0.824 0.861 0.807 0.625
RS 500 - 0.819 0.859 0.853 0.691
RS 1000 - 0.835 0.872 0.809 0.637
RS 5000 - 0.837 0.835 0.826 0.796
RS 25000 - 0.840 0.856 0.859 0.743
BO 50 Y 0.820 0.860 0.886 0.828
BO 50 N 0.826 0.834 0.889 0.833
BO 100 Y 0.825 0.850 0.884 0.843
BO 100 N 0.817 0.841 0.890 0.817
BO 250 Y 0.831 0.846 0.891 0.820
BO 250 N 0.826 0.858 0.893 0.831
BO 500 Y 0.830 0.845 0.886 0.824
BO 500 N 0.844 0.824 0.892 0.844
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Table 5: Grouped 5-fold CV and external validation (Val.) performance of selected classifiers for the BVN and mortality
(Mort.) tasks. BO runs were performed in the transformed hyperparameter space with the EI acquisition function and 25
initialization configurations at the indicated evaluation budgets. Bold numbers indicate the best performance for a column.
Model
HO
Type
No. of
Evals. ARD
BVN
CV
BVN
Val.
Mort.
CV
Mort.
Val.
RBF
GS 10 - 0.808 0.862 0.758 0.736
GS 50 - 0.814 0.853 0.797 0.739
GS 100 - 0.814 0.853 0.800 0.782
GS 250 - 0.814 0.853 0.801 0.749
GS 500 - 0.815 0.853 0.801 0.749
GS 1000 - 0.815 0.853 0.839 0.708
GS 5000* - 0.815 0.853 0.839 0.708
BO 10 Y 0.813 0.851 0.817 0.678
BO 10 N 0.815 0.852 0.832 0.772
BO 50 Y 0.815 0.851 0.800 0.748
BO 50 N 0.816 0.852 0.802 0.735
BO 100 Y 0.816 0.852 0.810 0.727
BO 100 N 0.816 0.852 0.801 0.749
XGB
RS 50 - 0.809 0.830 0.880 0.819
RS 100 - 0.813 0.827 0.885 0.819
RS 250 - 0.812 0.826 0.885 0.829
RS 500 - 0.810 0.829 0.885 0.826
RS 1000 - 0.810 0.822 0.885 0.822
RS 5000 - 0.813 0.830 0.888 0.823
RS 25000 - 0.815 0.860 0.889 0.816
BO 50 Y 0.809 0.828 0.883 0.824
BO 50 N 0.811 0.827 0.882 0.815
BO 100 Y 0.810 0.826 0.885 0.824
BO 100 N 0.811 0.830 0.883 0.826
BO 250 Y 0.810 0.820 0.887 0.816
BO 250 N 0.811 0.817 0.886 0.823
BO 500 Y 0.814 0.823 0.889 0.823
BO 500 N 0.808 0.826 0.883 0.811
MLP
RS 50 - 0.818 0.860 0.762 0.631
RS 100 - 0.814 0.863 0.785 0.640
RS 250 - 0.824 0.861 0.807 0.625
RS 500 - 0.819 0.859 0.853 0.691
RS 1000 - 0.835 0.872 0.809 0.637
RS 5000 - 0.837 0.835 0.826 0.796
RS 25000 - 0.840 0.856 0.859 0.743
BO 50 Y 0.815 0.840 0.890 0.821
BO 50 N 0.819 0.873 0.888 0.824
BO 100 Y 0.822 0.878 0.893 0.836
BO 100 N 0.817 0.858 0.889 0.837
BO 250 Y 0.824 0.863 0.889 0.831
BO 250 N 0.831 0.856 0.892 0.836
BO 500 Y 0.833 0.858 0.890 0.833
BO 500 N 0.832 0.843 0.892 0.809
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Figure 4: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for GS/RS evaluation budgets with the UCB acquisition function and 25 initialization configurations in the
original hyperparameter space. Similar layout to Figure 3 except that the indicated evaluation budgets only apply to
GS/RS-selected classifiers. BO-selected classifiers are taken from 100-evaluation (RBF) or 500-evaluation (XGB and MLP)
runs.
A. B.
Figure 5: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for BO evaluation budgets with the EI acquisition function and 25 initialization configurations in the
transformed hyperparameter space. Differences greater than 0 indicate better performance for the BO-selected classifier.
Classifiers were selected using either BO or GS/RS with the indicated number of evaluations. Points represent observed
differences while error bars represent 95% bootstrap confidence intervals of the difference in performance.
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Figure 6: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for GS/RS evaluation budgets with the EI acquisition function and 25 initialization configurations in the
transformed hyperparameter space. Similar layout to Figure 5 except that the indicated evaluation budgets only apply to
GS/RS-selected classifiers. BO-selected classifiers are taken from 100-evaluation (RBF) or 500-evaluation (XGB and MLP)
runs.
A. B.
Figure 7: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for BO-selected classifiers with or without ARD enabled. BO runs were performed with the UCB acquisition
function and 25 initialization configurations in the original hyperparameter space. Differences greater than 0 indicate better
performance for the ARD-enabled classifier. Points represent observed differences while error bars represent 95% bootstrap
confidence intervals of the difference in performance.
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Figure 8: Differences in classifier performance in internal (CV) and external validation on the BVN (A; mAUC) and mortality
(B; AUC) tasks for BO-selected classifiers with or without ARD enabled. BO runs were performed with the EI acquisition
function and 25 initialization configurations in the transformed hyperparameter space. Differences greater than 0 indicate
better performance for the ARD-enabled classifier. Points represent observed differences while error bars represent 95%
bootstrap confidence intervals of the difference in performance.
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